DAWN TAMAGNI: Open Payments
NPI 1033299920 · BOISE, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$442 in 13 payments from 7 companies in 2025. Trend: 2023 $564 · 2024 $320 · 2025 $442
Food & beverage: $410Education: $32
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 1 | $110 |
| Tandem Diabetes Care, Inc. | 2 | $96 |
| Novo Nordisk Inc | 4 | $85 |
| ABBVIE INC. | 2 | $60 |
| Corcept Therapeutics | 2 | $47 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $25 |
| Lilly USA, LLC | 1 | $19 |
Products named: AIRSUPRA, t:slim X2 Insulin Pump with Control-IQ, Rybelsus, Korlym, CREON, Ozempic, LINZESS, XIFAXAN.
Industry payments across ID — which companies pay providers there.
